RuncheyResearch
Back to Forecasting
WVEActive

Will Wave Life Sciences announce an equity offering or ATM program before key Q2 2026 clinical data readouts?

Resolves June 30, 2026(82d)
IG: 0.64

Current Prediction

24%
Likely No
Model Agreement94%
Predictions9 runs
Last UpdatedApril 8, 2026

Why This Question Matters

The Stress Scanner and Insider Investigator both flag the timing of any capital raise relative to clinical catalysts. Raising capital before key data readouts would suggest insiders lack confidence in near-term catalysts. Waiting until after positive data would be capital-efficient and shareholder-aligned.

GOVERNANCE_ALIGNMENTFUNDING_FRAGILITY

Prediction Distribution

0%25%50%75%100%
opus
sonnet
haiku
Range: 14% – 34%Aggregate: 24%
Individual Predictions(9 runs)
opusRun 1
22%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Biotech convention is raise when you can provides partial support, but $602m cash with q3 2028 runway means no urgency creates counterweight. Probability: 0.22.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency
opusRun 2
34%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Biotech convention is raise when you can provides partial support, but $602m cash with q3 2028 runway means no urgency creates counterweight. Probability: 0.34.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency
opusRun 3
25%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Biotech convention is raise when you can provides partial support, but $602m cash with q3 2028 runway means no urgency creates counterweight. Probability: 0.25.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency
sonnetRun 1
18%

Base rate evidence: $602m cash with q3 2028 runway means no urgency. Partial offset from biotech convention is raise when you can. Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Probability: 0.18.

$602M cash with Q3 2028 runway means no urgencyAdequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can
sonnetRun 2
14%

Base rate evidence: $602m cash with q3 2028 runway means no urgency. Partial offset from biotech convention is raise when you can. Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Probability: 0.14.

$602M cash with Q3 2028 runway means no urgencyAdequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can
sonnetRun 3
20%

Base rate evidence: $602m cash with q3 2028 runway means no urgency. Partial offset from biotech convention is raise when you can. Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Probability: 0.2.

$602M cash with Q3 2028 runway means no urgencyAdequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can
haikuRun 1
29%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Balance of evidence suggests 0.29 probability. Primary support: biotech convention is raise when you can. Main counterargument: $602m cash with q3 2028 runway means no urgency.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency
haikuRun 2
25%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Balance of evidence suggests 0.25 probability. Primary support: biotech convention is raise when you can. Main counterargument: $602m cash with q3 2028 runway means no urgency.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency
haikuRun 3
24%

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficient. Balance of evidence suggests 0.24 probability. Primary support: biotech convention is raise when you can. Main counterargument: $602m cash with q3 2028 runway means no urgency.

Adequate runway and near-term catalyst favor waiting; raising at current depressed price is capital-inefficientBiotech convention is raise when you can$602M cash with Q3 2028 runway means no urgency

Resolution Criteria

Resolves YES if Wave announces any equity offering, ATM program, or convertible note issuance before June 30, 2026 (prior to expected WVE-007 6-month data). Resolves NO if no capital raise is announced before that date.

Resolution Source

SEC filings (S-3, prospectus supplement), Wave press releases

Source Trigger

Capital raise expected within 12-18 months; timing relative to clinical catalysts signals management confidence or desperation

insider-investigatorGOVERNANCE_ALIGNMENTHIGH
View WVE Analysis

Full multi-lens equity analysis